Linus Wahnschaffe
Overview
Explore the profile of Linus Wahnschaffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, et al.
Blood
. 2024 Jun;
144(15):1595-1610.
PMID: 38941598
T-prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm associated with marked chemotherapy resistance and continued poor clinical outcomes. Current treatments, that is, the CD52-antibody alemtuzumab, offer transient responses, with relapses...
2.
Otte M, Stachelscheid J, Glass M, Wahnschaffe L, Jiang Q, Lone W, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173993
T-prolymphocytic leukemia (T-PLL) is a rare and mature T-cell malignancy with characteristic chemotherapy-refractory behavior and a poor prognosis. Molecular concepts of disease development have been restricted to protein-coding genes. Recent...
3.
Herbst S, Vesterlund M, Helmboldt A, Jafari R, Siavelis I, Stahl M, et al.
Nat Commun
. 2022 Oct;
13(1):6226.
PMID: 36266272
Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond the currently established genomic and transcriptomic-based diagnostics. The relevance of proteomics for disease classifications remains...
4.
Mikhaylenko N, Wahnschaffe L, Herling M, Roeder I, Seifert M
PLoS One
. 2022 Sep;
17(9):e0274463.
PMID: 36129940
T-cell prolymphocytic leukemia (T-PLL) is a rare blood cancer with poor prognosis. Overexpression of the proto-oncogene TCL1A and missense mutations of the tumor suppressor ATM are putative main drivers of...
5.
Braun T, Stachelscheid J, Bley N, Oberbeck S, Otte M, Muller T, et al.
Cancer Res
. 2022 Mar;
82(9):1818-1831.
PMID: 35259248
Significance: The identification of AGO2-mediated activation of oncogenic T cells through signal amplifying protein-protein interactions advances the understanding of leukemogenic AGO2 functions and underlines the role of aberrant TCR signaling...
6.
Pflug N, Littauer A, Beverungen D, Sretenovic A, Wahnschaffe L, Braun T, et al.
Front Oncol
. 2022 Jan;
11:775313.
PMID: 35070980
Large granular lymphocyte leukemia (LGLL) represents a rare group of diseases with considerable difficulties in their correct diagnostic workup and therapy. The major challenges lie in their distinction from reactive...
7.
8.
9.
Braun T, Glass M, Wahnschaffe L, Otte M, Mayer P, Franitza M, et al.
Haematologica
. 2021 Feb;
107(1):187-200.
PMID: 33543866
T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic mature T-cell malignancy. It typically presents with exponentially rising lymphocyte counts, splenomegaly, and bone marrow infiltration. Effective treatment options are scarce and a...
10.
Cuesta-Mateos C, Fuentes P, Schrader A, Juarez-Sanchez R, Loscertales J, Mateu-Albero T, et al.
Biomark Res
. 2020 Oct;
8:54.
PMID: 33110606
Supplementary Information: accompanies this paper at 10.1186/s40364-020-00234-z.